Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) develops, manufactures, markets and distributes medicines, including generic drugs, biosimilars and branded pharmaceuticals. Its three reportable segments are Affordable Medicines, Specialty and AvKARE. Affordable Medicines offers more than 280 U.S. product families across… From the company’s description.
Over the twelve months to Jun 30, 2026, Amneal Pharmaceuticals, Inc. reported revenue of $3.12B, up 9.3% from a year earlier, and net income of $215.32M. Its operating margin was 14.6%, and operations generated $200.78M in cash. In fiscal 2025, it reported revenue of $3.02B, up 8.0% from fiscal 2024, and net income of $127.93M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Amneal Pharmaceuticals, Inc. does
In the company’s own words
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) develops, manufactures, markets and distributes medicines, including generic drugs, biosimilars and branded pharmaceuticals. Its three reportable segments are Affordable Medicines, Specialty and AvKARE. Affordable Medicines offers more than 280 U.S. product families across dosage forms such as oral solids, injectables, inhaled drugs and biosimilars, selling mainly to wholesalers, pharmacies, hospitals and institutions. Specialty develops, promotes and sells branded products focused primarily on central nervous system and endocrine disorders, including CREXONT, RYTARY, UNITHROID and Brekiya, marketed to physicians and healthcare providers. AvKARE distributes pharmaceuticals and other products to U.S. government agencies, retail and institutional customers, and repackages medicines and vitamins under the AvKARE and AvPAK names. The company operates principally in the United States, India and Ireland, with manufacturing and research facilities across those countries. In 2025, it served approximately 1,300 customers, including more than 1,100 through AvKARE; four major customers together accounted for about 71% of consolidated net revenue. Its website is not stated in the provided company information.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Fiscal year end
- December
- CIK
- 1723128
- SIC
- 2834
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Amneal Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Amneal Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Amneal Pharmaceuticals, Inc.’s bonds, as funds hold them
Funds report holding 1 issues of Amneal Pharmaceuticals, Inc.’s debt, $177.99M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 6.88%, maturing 2032 to 2032.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Amneal Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Amneal Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Amneal Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”